Published in Clin Exp Nephrol on April 11, 2012
Systemic lupus erythematosus disease activity index 2000. J Rheumatol (2002) 6.11
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol (2009) 5.02
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med (2001) 2.77
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis (2010) 2.38
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med (1996) 2.17
Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol (2008) 1.98
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int (2000) 1.50
Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (2000) 1.50
Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol (2007) 1.39
Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis (2002) 1.39
Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med (1995) 1.35
Update on the treatment of lupus nephritis. Kidney Int (2006) 1.33
Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum (2004) 1.27
Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis (2002) 1.21
Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int (2005) 1.18
Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc (1996) 1.12
Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis (2010) 1.03
Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol (2009) 1.03
Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol (2009) 0.99
Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) (2008) 0.99
Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol (2005) 0.95
Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus (2011) 0.91
Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod Rheumatol (2007) 0.91
Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus (2010) 0.85
Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol (2008) 0.85
Thirty years of cyclophosphamide: assessing the evidence. Lupus (2007) 0.84
Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol (2007) 0.83
Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. Mod Rheumatol (2009) 0.83
Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the tohoku pediatric study group. Nephron Clin Pract (2008) 0.82
Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. Mod Rheumatol (2010) 0.81
Good response of membranous lupus nephritis to tacrolimus. Clin Nephrol (2006) 0.81
Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. Mod Rheumatol (2009) 0.80
Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate. Mod Rheumatol (2009) 0.78
Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab. Mod Rheumatol (2009) 0.77
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
Simultaneous combined supra-infrasellar approach for giant/large multilobulated pituitary adenomas. World Neurosurg (2011) 2.76
Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis (2007) 2.74
Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol (2009) 2.66
Relationship between metabolic syndrome and proteinuria in the Japanese population. Intern Med (2006) 2.58
Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol (2007) 2.58
Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum (2004) 2.52
Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens (2008) 2.42
Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A (2005) 2.31
Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol (2007) 2.20
Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol (2011) 2.12
Effects of icodextrin peritoneal dialysis solution on the peritoneal membrane in the STZ-induced diabetic rat model with partial nephrectomy. Nephrol Dial Transplant (2009) 2.08
CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum (2002) 2.01
Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol (2012) 1.95
Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes (2003) 1.91
Relationship between metabolic syndrome and cigarette smoking in the Japanese population. Intern Med (2006) 1.88
NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol (2005) 1.78
Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res (2008) 1.70
Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) (2013) 1.69
Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol (2011) 1.69
The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther (2006) 1.67
HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant (2003) 1.57
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol (2011) 1.52
Abrupt enlargement of adrenal incidentaloma: a case of isolated adrenal metastasis. Endocr J (2005) 1.51
Establishment and characterization of renal progenitor like cells from S3 segment of nephron in rat adult kidney. FASEB J (2005) 1.45
The MUSCAT study: a Multicenter PROBE Study Comparing the Effects of Angiotensin II Type-1 Receptor Blockers on Self-Monitored Home Blood Pressure in Patients with Morning Hypertension: study design and background characteristics. Hypertens Res (2008) 1.44
[A preliminary report of national research on podocytic infolding glomerulopathy]. Nihon Jinzo Gakkai Shi (2007) 1.44
A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol (2009) 1.44
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res (2013) 1.42
An extra-adrenal abdominal pheochromocytoma causing ectopic ACTH syndrome. Am J Hypertens (2005) 1.42
Mandibular subluxation stabilized by mouthpiece for distal internal carotid artery exposure in carotid endarterectomy. J Vasc Surg (2010) 1.40
Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol (2010) 1.39
Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res (2008) 1.39
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol (2006) 1.31
Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum (2006) 1.28
ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes. Clin Exp Nephrol (2012) 1.27
Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther (2010) 1.24
A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo. J Pharmacol Exp Ther (2003) 1.23
Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol (2006) 1.23
TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem Biophys Res Commun (2007) 1.23
Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes (2004) 1.23
Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene (2004) 1.23
Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol (2013) 1.20
Clinical features of non-diabetic renal diseases in patients with type 2 diabetes. Diabetes Res Clin Pract (2005) 1.20
Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension (2004) 1.19
Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol (2008) 1.19
Therapeutic approach for diabetic nephropathy using gene delivery of translocase of inner mitochondrial membrane 44 by reducing mitochondrial superoxide production. J Am Soc Nephrol (2006) 1.18
Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Clin Exp Nephrol (2013) 1.17
Enhanced interaction between focal adhesion and adherens junction proteins: involvement in sphingosine 1-phosphate-induced endothelial barrier enhancement. Microvasc Res (2009) 1.16
Design and methods of a strategic outcome study for chronic kidney disease: Frontier of Renal Outcome Modifications in Japan. Clin Exp Nephrol (2009) 1.15
A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One (2013) 1.15
Daily walking reduces visceral adipose tissue areas and improves insulin resistance in Japanese obese subjects. Diabetes Res Clin Pract (2002) 1.15
Proposal of podocytic infolding glomerulopathy as a new disease entity: a review of 25 cases from nationwide research in Japan. Clin Exp Nephrol (2008) 1.14
Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) (2008) 1.14
Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes (2007) 1.13
Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation (2003) 1.11
Catalase deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. Kidney Int (2005) 1.10
Japan Renal Biopsy Registry: the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol (2011) 1.08
Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes (2005) 1.08
Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther (2004) 1.07
Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes (2011) 1.07
Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans. J Clin Endocrinol Metab (2002) 1.06
Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol (2010) 1.05
Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol (2008) 1.05
Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol (2008) 1.05
Clinical correlates of ambulatory BP monitoring among patients with CKD. Clin J Am Soc Nephrol (2013) 1.03
Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care (2005) 1.02
Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model. Biochem Biophys Res Commun (2004) 1.01
Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology (2012) 1.01
Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am J Physiol Renal Physiol (2011) 1.00
Acatalasemia sensitizes renal tubular epithelial cells to apoptosis and exacerbates renal fibrosis after unilateral ureteral obstruction. Am J Physiol Renal Physiol (2004) 1.00
Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology (2011) 1.00
Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study. Clin Exp Nephrol (2011) 0.99
Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol (2003) 0.99
Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol (2005) 0.99
The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis. Rheumatol Int (2004) 0.99
Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes (2006) 0.99
2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes (2006) 0.99
Angiogenesis and chronic kidney disease. Fibrogenesis Tissue Repair (2010) 0.99
Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res (2003) 0.98
Gene delivery of Tim44 reduces mitochondrial superoxide production and ameliorates neointimal proliferation of injured carotid artery in diabetic rats. Diabetes (2005) 0.98
Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther (2014) 0.98
Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant (2005) 0.98
Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens (2006) 0.97
Purification and characterization of a soluble form of rat liver NADPH-cytochrome P-450 reductase highly expressed in Escherichia coli. Protein Expr Purif (2003) 0.97
Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease. Clin Exp Nephrol (2013) 0.97
Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J Endocrinol (2008) 0.97
Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes (2009) 0.96
Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin. Diabetes (2012) 0.96
The role for HNF-1beta-targeted collectrin in maintenance of primary cilia and cell polarity in collecting duct cells. PLoS One (2007) 0.96
Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. J Clin Endocrinol Metab (2012) 0.96
Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes (2012) 0.95
Significance of 8-hydroxy-2'-deoxyguanosine levels in patients with chronic renal failure. Nephrology (Carlton) (2003) 0.95
Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria). Nephrol Dial Transplant (2013) 0.95
Long-term results of tonsillectomy as a treatment for IgA nephropathy. Acta Otolaryngol Suppl (2004) 0.94
Hypokalemic paralysis and osteomalacia secondary to renal tubular acidosis in a case with primary Sjögren's syndrome. Mod Rheumatol (2006) 0.94
Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray. PLoS One (2013) 0.93
Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial. Clin J Am Soc Nephrol (2011) 0.93